Trump pushes psychedelics into the policy mainstream with new research order
Support from veterans and some health officials meets skepticism from critics warning of safety risks and hype
A dramatic shift in federal drug policy
President Donald Trump has signed an executive order directing federal agencies to accelerate research and potential approval of psychedelic drugs — a move that signals one of the most significant shifts in U.S. drug policy in decades.
The order instructs the Food and Drug Administration to speed up clinical trials and review pathways for substances including psilocybin (the active compound in “magic mushrooms”), MDMA (ecstacy), LSD, and ibogaine, all of which are currently classified as Schedule I drugs under federal law, according to The Washington Post.
The administration framed the move as a response to the nation’s worsening mental health crisis, particularly among military veterans struggling with post-traumatic stress disorder (PTSD), depression, and addiction, Reuters reported.
Veterans and mental health drive the push
At the center of the policy shift is a growing coalition of veterans, lawmakers, and advocates who argue that traditional treatments have failed many patients.
Trump highlighted the potential of ibogaine — a psychedelic derived from an African plant — which has shown promise in treating PTSD and opioid addiction. The administration committed at least $50 million to research into ibogaine and other psychedelic therapies.
Supporters say the urgency is clear: thousands of U.S. veterans die by suicide each year, and many have traveled abroad for psychedelic treatments that remain illegal domestically.
Health officials, including Health Secretary Robert F. Kennedy Jr., emphasized the need to explore “all options” for treatment-resistant conditions.
What the order actually does
The executive order lays out several concrete steps:
Fast-tracking FDA reviews for certain psychedelic drugs, potentially using “breakthrough therapy” pathways;
Expanding clinical trials, including first-in-U.S. human trials for ibogaine;
Increasing federal funding for research and development;
Exploring rescheduling of psychedelics that receive FDA approval;
Allowing limited access pathways, such as “right-to-try” options for some patients.
If successful, the policy could lead to the first federally approved psychedelic treatments in the U.S., possibly as soon as later this year, according to officials.
The science: promise — and uncertainty
Psychedelics have drawn increasing attention from researchers over the past decade. Early studies suggest compounds like psilocybin may help alleviate depression and anxiety, particularly in treatment-resistant cases, though results are often modest and short-term.
Ibogaine has also shown potential benefits, particularly for addiction and PTSD, but carries significant risks — including cardiac complications and, in some cases, death, according to AP News.
Researchers say more rigorous, large-scale trials are needed before these therapies can be widely adopted.
Critics warn of risks and “overhype”
Not everyone is convinced the policy is moving at the right pace.
Some public health experts argue that psychedelics remain poorly understood and could pose safety risks if rushed through the approval process. Critics also warn that enthusiasm for these treatments may outpace the science.
“There’s concern about promoting unproven therapies,” one prominent drug policy critic said, pointing to limited long-term data and potential side effects, The Washington Post said.
Others caution that focusing on experimental treatments could distract from more immediate needs, such as expanding access to existing mental health care.
A bipartisan — and cultural — shift
Despite the concerns, interest in psychedelics has grown across the political spectrum.
States including Oregon and Colorado have already moved to legalize or decriminalize psilocybin in controlled settings, reflecting broader public openness to alternative therapies.
High-profile advocates — from veterans’ groups to media personalities — have helped push the issue into the mainstream, reframing psychedelics from counterculture substances to potential medical tools.
What this means for consumers
For now, psychedelic drugs remain illegal for most uses in the United States, and consumers should be wary of clinics or providers making unproven claims.
But the federal push could eventually lead to:
New treatment options for PTSD, depression, and addiction;
Insurance and cost questions if therapies are approved but expensive to deliver;
A surge in telehealth and wellness marketing, raising fraud and safety concerns;
Regulatory gray areas during the transition from prohibition to medical use.
In short, psychedelics are moving rapidly from the fringe toward the medical mainstream — but the science, regulation, and consumer protections are still catching up.
Affordability Watch: Will psychedelic therapy be the next expensive “breakthrough”?
Why it could get expensive fast
Even if drugs like psilocybin or MDMA win approval, the biggest cost driver won’t be the pill — it will be the therapy wrapped around it.
Most current clinical models involve:
Multiple prep sessions with licensed therapists;
Supervised dosing sessions lasting 6–8 hours;
Follow-up integration therapy.
That structure can require 20–40 hours of clinician time per patient, pushing total costs into the thousands.
Early price signals
Legal psychedelic services already operating in places like Oregon suggest:
$3,000–$7,000 for psilocybin-assisted therapy sessions
Higher-end concierge-style programs exceeding $10,000
Scaling that nationally — especially with medical oversight — could push prices even higher.
Insurance: the big unknown
The key affordability question is whether insurers will treat psychedelic therapy like:
Mental health treatment (covered);
Or experimental/alternative care (not covered).
Even if approved, insurers may:
Require strict eligibility criteria;
Limit the number of sessions;
Delay coverage decisions for years.
That could leave many patients paying out-of-pocket — at least initially.
Equity concerns
Critics warn of a familiar pattern:
Wealthier patients gain early access;
Lower-income patients face long waits or no access;
A “two-tier” mental health system emerges.
Bottom line
Psychedelic therapy could be transformative — but without clear insurance pathways and pricing controls, it risks becoming another breakthrough that many patients simply can’t afford.
Fraud Watch: Psychedelic hype creates new scam risks
A fast-moving gray market
Even before federal approval, a patchwork of:
Wellness retreats;
Underground therapy networks;
Online “microdosing” shops
has emerged — often operating in legally ambiguous or outright illegal territory.
Experts say the new federal push could supercharge that market, creating opportunities for bad actors.
Common red flags
Watch for providers who:
Claim psychedelic therapy is “FDA-approved” when it isn’t;
Guarantee cures for PTSD, depression, or addiction;
Require large upfront payments;
Offer treatment without medical screening or supervision.
Dangerous products online
Scammers are also selling:
Fake psilocybin products;
Misidentified mushrooms;
Synthetic substances marketed as “natural.”
These can pose serious health risks, including poisoning or dangerous drug interactions.
The retreat trap
Some consumers are traveling domestically or overseas for psychedelic retreats that:
Lack medical oversight;
Use unverified substances;
Provide little or no follow-up care.
In some cases, patients have reported:
Medical emergencies;
Psychological distress;
Financial exploitation.
What regulators are watching
Agencies like the Federal Trade Commission are likely to scrutinize:
False advertising claims;
Impersonation of legitimate providers;
Unfair or deceptive billing practices.
Expect enforcement to ramp up as the market grows.
How to protect yourself
Verify whether a treatment is legally approved;
Check provider credentials and licensing;
Avoid upfront fees for “guaranteed” results;
Be skeptical of online-only sellers.
Bottom line
As psychedelics move toward the medical mainstream, scams will follow the hype. Consumers should treat bold claims and easy access with caution — especially while the rules are still evolving.